Tag: Arthritis: Rheumatoid

Any DMARD use recorded at 56 percent of rheumatologist visits and 30 percent of primary care provider visits

Limited evidence suggests that continuing biological DMARDs may lower risk for disease flares without increasing risk for postop complications

Adverse events common during first year of methotrexate therapy for early rheumatoid arthritis, but most not serious

Substantial proportion of overall risk may be preventable by healthy lifestyle

Risk for severe progression higher for patients in top quintile for PRS; association stronger in patients who were younger at disease onset

Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met

Those presenting with fatigue early likely to see it persist

MRI-detected tenosynovitis independently associated with progression to rheumatoid arthritis

Machine learning integrating clinical and genomic data can predict methotrexate treatment response in early rheumatoid arthritis

Anti-CCP3 antibodies were predictive for the development of ultrasound synovitis in anti-CCP2+ at-risk individuals